Brain Tumor Diagnosis And Therapeutics Market Report

Brain Tumor Diagnosis And Therapeutics Market Analysis By Type (MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing, And EEG), By Region, And Segment Forecasts, 2014 - 2025

Published: January 2017  |  100 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-349-2

Industry Insights

The global brain tumor diagnosis and therapeutics market was valued at USD 354.9 million in 2015 and is expected to grow at a CAGR of 8.1% over the forecast period. Rising prevalence of such cancer and growing geriatric population are key drivers expected to nurture growth of brain tumor diagnosis market worldwide.

As per statistics published by the WHO in 2012, more than14 million new cases of cancer and about 8.2 million deaths were reported; thus alerting the healthcare fraternity to the augmenting growth of the disease. Furthermore, it stated that morbidity is expected to increase by about 70.0% over the next two decades. Similar data was published by the Global Health Observatory (GHO) in 2015, which stated that the number of premature deaths due to cancer is expected to increase by 44.0% by 2030.

U.S. brain tumor diagnosis market, by type, 2014 - 2025 (USD Million)

U.S. brain tumor diagnosis market

As per the Central Brain Tumor Registry of the United States (CBTRUS) statistical report 2016, an estimated 79,270 new cases of primary malignant, nonmalignant, and other CNS cancers are anticipated to be diagnosed in the U.S. in 2017 (26,070 primary malignant and 53,200 nonmalignant). Increasing prevalence of brain cancer cases across the globe is expected to propel the demand of brain tumor diagnosis over the forecast period.

Population above 60 years of age forms the target demographic segment for this vertical, as this population subset is more prone to neurological conditions. Advancement of diagnostics equipment increases the lifespan of this demographic and improves the quality of life for those suffering from neurological conditions. Hence, presence of a large geriatric population pool is considered as a vital driver for this industry.

Type Insights

Computer Tomography (CT) dominated the type segment with over 38.0%of the market share in 2015 and is expected to witness lucrative growth during the forecast period. It displays higher efficiency in delivering doses of cancer tissue damaging radiation in comparison to conventional X-rays. This augments use of CT scans for diagnosing diseases.

According to an independent survey, around 3 million CT scans are carried out each year in the UK. Furthermore, this scanning rate per person is approximately five times greater than that in the U.S., which promises lucrative growth of the segment over the forecast period. In addition, initiatives taken by various governments worldwide to raise awareness regarding brain tumor prevalence and diagnosis are expected to positively impact growth.

MRI follows the CT scan segment and is expected to register profitable growth over the forecast period. These devices are utilized by numerous neurologists because of their accuracy in analysis. Furthermore, they also provide detailed images of the anatomy of the brain, thereby helping in accurately identifying the location of possible cancerous tissue. Amalgamation of CT scan with PET technology (PET-CT Scan) is used to in case of analysis of lumps while a patient is undergoing treatment. The PET-CT scan is often used for diagnosis when CT scan and MRI are unable to provide enough information.

Therapeutics Insights

Owing to the rising incidence of brain tumor and augmenting death rate, the market for its treatment is also anticipated to witness lucrative growth over the forecast period. Various government and independent organizations, such as the WHO, American Brain Tumor Association, and International Brain Tumor Alliance, are working toward supporting availability of treatment and conducting research on novel cure for the disease.

On the basis of therapeutics, the market has been segmented into radiation therapy, chemotherapy, targeted therapy, surgery, and immunotherapy. As of 2015, surgery is anticipated to contribute highest revenue to the brain tumor and therapeutics market. The low awareness levels and limited treatment options leading to aggravation of the disease to grade IV stage, are expected to boost the demand for surgeries.

Radiation therapy is anticipated to exhibit significant growth over the forecast period as this therapy kills the cancer cells by using X-rays, gamma rays, or protons and is the second best choice after surgery.

Rising preference for alkylating neoplastic agents, such as carmustine, vincristine, lomustine, procarbazine, and temozolomide, for chemotherapy is expected to contribute favorably to the growth of this vertical. For instance, various new drugs are in pipeline of leading players, such as varlilumab by Celldex Therapeutics.

Global brain tumor diagnosis market, by region, 2015

Global brain tumor diagnosis market

Regional Insights

North America held more than 45.0% share in the global brain tumor diagnosis and therapeutics market in 2015. Developed healthcare infrastructure, greater per capita healthcare spending, and comparatively higher awareness regarding advanced technologies are certain impact rendering factors.

Europe is expected to contribute significantly to this space over the forecast period, which can be attributed to the increasing prevalence of malignant cancers in the countries like the UK. For instance, as per statistics provided by the Office for National Statistics, UK, in 2014, around 10,981 new cases were registered in the region.

Competitive Insights

Some of the key players operating in this space are GE Healthcare; Hitachi, Ltd.; Philips Healthcare; Siemens Healthineers; Toshiba Corporation; Fujifilm Corporation; Shimadzu Corporation; and Carestream Health.

New product development, geographical expansion, collaborations, mergers & acquisitions, and pricing strategies are the key undertakings of these players in this vertical. For instance, in November 2016, Toshiba Corporation launched new Vantage Galan 3T MR scan, an advanced imaging technique with improved high-quality imaging, which finds high application in neurological cancer diagnosis.

Report Scope

 

Attribute

Details

Base year for estimation

2015

Actual estimates/Historical data

2014 - 2015

Forecast period

2016 - 2025

Market representation

Revenue in USD Million & CAGR from 2016 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America & MEA

Country scope

U.S., Canada, UK, Germany, Japan, India, Brazil, Mexico, South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research, Inc. has segmented the brain tumor diagnosis and therapeutics market on the basis of type, therapeutics, and region:

  • Type Outlook (Revenue, USD Million, 2014 - 2025)

    • MRI

    • CT Scan

    • Tissue Sampling

    • PET-CT Scan

    • Cerebral Arteriogram

    • Lumbar Puncture

    • Molecular Testing

    • EEG

  • Therapeutics Outlook (Revenue, USD Million, 2014 - 2025)

    • Surgery

    • Radiation Therapy

    • Chemotherapy

    • Immunotherapy

    • Targeted Therapy

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • Japan

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East and Africa (MEA)

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA